AnaptysBio Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
/ 
Frequently asked questions
To buy AnaptysBio Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for AnaptysBio Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for AnaptysBio Inc. is ANAB:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
AnaptysBio Inc. has its primary listing on NASDAQ. You can trade AnaptysBio Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, AnaptysBio Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include AnaptysBio Inc. as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like AnaptysBio Inc..